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Objectives: Osteoporosis treatment involves several therapeutic tools, includ-
ing long-term drug therapy. Subjects with chronic disorders are more likely to be 
non-adherent and/or non-persistent to treatment than those with other diseases. 
Adherence is the extent to which patients take medication as prescribed by their 
physicians, whereas persistence is the time from treatment initiation to discontinu-
ation. Lack of persistence is common among subjects using oral anti-osteoporotic 
drugs, and leads to increased risk of fragility fracture. The aim of our study is to 
analyze the rates and reasons for discontinuation of anti-osteoporotic drugs in the 
Campania Region. MethOds: The study was a retrospective cohort study. Patients, 
aged ≥ 40 years, were enrolled if at least one prescription for any antiosteoporotic 
drugs had been filled from July 1, 2009 through June 30, 2010. Data were retrieved 
from an administrative database of medications prescription in Campania region. 
Patients were followed from the index date until the antiosteoporotic therapy dis-
continuation or end of the observation period (June, 30, 2011). Results: A total of 
30,048 were incident users of anti-osteoporotic drugs: 1, 731 (5.8%) males and 28,317 
(94.2%) females. The mean age [SD] of the cohort was 69.0 [10.0] years. Weekly bis-
phosphonate (51.1%), was the most commonly prescribed drug. In the overall cohort 
study, persistence rates were 34, 8% after 6 months, 13, 4% at one year. A multivariate 
Cox proportional hazard analysis showed that daily regimen (HR 1,9) treatments 
remained at a higher risk of early discontinuation compared to weekly regimen 
therapies. Patients who started treatment with a co-prescription with calcium and 
vitamin D had a lower risk of early discontinuation (HR 0.7). cOnclusiOns: Our 
data showed that the persistence to osteoporosis therapy is significantly worse 
than reported in literature. A better osteoporosis management should include drugs 
with less frequent dosing, to obtain both an increase in rate of persistence and a 
reduction in side-effect.
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Objectives: In this study we determined the characteristics of patients with RA who 
used these aids, and the association of reminder use with adherence. MethOds: 
201 patients with RA were included in this prospective cohort study examining 
treatment adherence. At baseline patients were asked if they used any special 
reminders such as pill containers, calendars, or diaries. Patients completed two self-
reported adherence questionnaires: the Compliance Questionnaire Rheumatology 
and the Adult AIDS Clinical Trials Group adherence questionnaire. Disease activity 
measures included number of swollen joints, number of tender joints, disease activ-
ity score (DAS28), and patient global assessment. Functional status was evaluated 
with the modified Health Assessment Questionnaire (MHAQ). Results: Mean age 
of the patients was 51 years, 75% were female, 53% were Hispanic, 25% white, and 
21% African American. Sixty-eight (34%) patients reported using a reminder: 53 
(26%) used special pill containers, 12 (6%) used calendars, and 3 (1%) diaries. Factors 
associated with the use of reminders were older age (p= 0.004), being white vs. 
Hispanic or African American (p= 0.003), being male vs. female (p= 0.005). Working 
patients were less likely to report using reminders (p= 0.006). No association was 
observed between education levels and use of aids. Use of reminders was associ-
ated with domains of self-reported adherence: adherence while away from home 
(r= 0.16, p= 0.03), when busy (r= 0.16, p= 0.03), and when running out of pills (r= 0.15, 
p= 0.04). cOnclusiOns: Older patients, males, and whites were more likely to use 
these aids, more often pill containers. Our study shows that reminders can assist 
patients with RA in taking their medications, particularly in situations when they 
are most prone to forget including being away from home or busy. Use of reminders 
should be encouraged by providers as a low cost aid to enhance adherence.
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Objectives: The objective of this study was to describe persistence with subcu-
taneous biologic over 12 months for newly treated PsA patients and evaluate the 
impact of prior DMARD use. MethOds: This was a retrospective analysis using IMS 
Disease Analyzer-Germany, an electronic medical records database. Adult (≥ 18 years 
of age) PsA patients who initiated therapy with subcutaneous biologics between 
January 1, 2009 and June 30, 2012 were included in the analysis. The first subcutane-
ous biologic prescription date served as their index date. Continuous observation 
of at least 12 months pre- and post-index date was required. Patients who were 
prescribed any biologic during the pre-index period or diagnosed with rheumatoid 
arthritis, ankylosing spondylitis, crohn’s disease, or ulcerative colitis during the 
study period were excluded from the study population. A chi-square test was used 
to measure differences between patients with and without use of pre-index DMARD. 
A multivariate logistic regression was created to assess the impact of DMARD use 
on persistence, controlling for baseline characteristics. Results: A total of 197 
biologic-naïve PsA patients were selected. Of these, 89 were free of PsO. The mean 
(SD) age of the patients was 49 (11) years, with 50% being female. The majority of 
patients (61%) indexed on adalimumab, while the remainder indexed on etanercept 
(35%) and golimumab (4%). In the overall PsA population, the persistence rate with 
the index subcutaneous biologic was 54.3%, with similar results among those with 
and without DMARD use (53% vs 56%, respectively). Multivariate analysis did not 
identify any significant predictors for persistence, including DMARD use (OR: 1.05; 
A systematic review identified retrospective and prospective observational stud-
ies reporting 12-, 18-, or 24-month persistence with denosumab, an osteoporosis 
therapy approved in 2010. Searches covered the period January 2011─May 2014 and 
were conducted in the PubMed and EMBASE databases, and conference abstract 
supplements from ACR, AMCP, ASBMR, WCO-IOF-ESCEO, and ISPOR. To be eligible, 
studies needed to report at least one estimate of persistence with denosumab in 
patients with osteoporosis, have a clear definition of persistence, and be in English 
language. Using a random effects model, pooled estimates of denosumab per-
sistence were calculated for retrospective and prospective studies separately. A 
subgroup analysis was conducted based on geographical regions. Results: The 
search identified 338 unique citations in PubMed and EMBASE, and 200 confer-
ence abstracts. After applying the eligibility criteria, 11 studies were included in the 
final review and meta-analysis (7 retrospective; 4 prospective). All studies reported 
at least one estimate of 12-month persistence; 9 studies included females only. 
For retrospective studies, the pooled persistence estimates were 74.6% (95% CI: 
65.4-82.9) at 12 months, 67.6% (65.2-70.0) at 18 months, and 57.2% (51.8-62.5) at 24 
months. For prospective studies, the pooled estimate of 12-month persistence was 
89.0% (95% CI: 84.6-92.7). In the subgroup analysis, European studies had higher 
pooled 12-month persistence estimates compared with North American studies 
(retrospective: 78.6% vs. 68.9%; prospective: 91.5% vs. 85.3%). cOnclusiOns: To 
our knowledge, this is the first systematic review and meta-analysis of persistence 
with denosumab in patients with osteoporosis. We identified a growing body of 
evidence, both prospective and retrospective, suggesting persistence to denosumab 
is higher than previously reported for other OP therapies1.1. Kothawala P, et al. Mayo 
Clinic. 2007; 82 (12): 1493-501.
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Objectives: This study examined persistence over 12 months for RA patients who 
were newly treated with subcutaneous biologics, and assessed if there are differ-
ences between patients with and without prior DMARDs experience. MethOds: 
In this retrospective cohort study using Electronic Medical Record database of IMS 
Disease Analyzer-Germany, adult (≥ 18 years old) RA patients with exposure to a 
subcutaneous biologic between January 1, 2009 and June 30, 2012 were identified. 
The first prescription date for the subcutaneous biologic agent was defined as 
their index date. Patients were excluded from the study if they were prescribed 
a biologic agent during the pre-index period, and/or diagnosed with ankylosing 
spondilitis, psoriatic arthritis, or other conditions treated with subcutaneous bio-
logics either pre- or post-index. A chi-square test was used to assess significant 
differences in the percentage of persistent patients between those with and with-
out DMARD use and a logistic regression model was used to control for differences 
in baseline demographic and clinical characteristics. Results: A total of 576 RA 
patients without prior biologic experience met the study selection criteria; 471 
were DMARD experienced and 105 were DMARD naive. The mean (SD) age of the 
patients was 57 (13), with 75% being female. The majority of patients indexed 
on etanercept (46%) or adalimumab (40%). Forty eight percent of the patients 
persisted on their index biologic over the 12 months post-index period, with the 
rate significantly higher among those with pre-index DMARD use (51% vs. 31%; 
p= 0.0012). After controlling for pre-index characteristics, patients with pre-index 
DMARD had 2.23 times the odds of being persistent compared to those without 
pre-index DMARDs (OR: 2.23, 95% CI: 1.37-3.62). cOnclusiOns: Approximately 
half of biologic naïve RA patients were persistent over a 12-month period with 
their index subcutaneous biologic, with rates significantly higher among patients 
with pre-index DMARD.
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Objectives: This study aimed to describe persistence with subcutaneous biologics 
among biologic naïve AS patients over 12 months, and to identify differences among 
patients with and without NSAID drug experience. MethOds: This retrospective 
study used IMS Disease Analyzer-Germany, an electronic medical records database. 
Data for adult (≥ 18 years of age) AS patients with a prescription for subcutaneous 
biologic between January 1, 2009 and June 30, 2012 were used for this analysis. The 
index date was the date of the first subcutaneous biologic prescription. Prescription 
for any biologic during the pre-index period or diagnosis for rheumatoid arthritis, 
psoriatic arthritis or other conditions treated with subcutaneous biologics either 
in pre- or post-index qualified patients for exclusion from the study. Differences 
between pre-index NSAID naïve and experienced patients were measured using a 
chi-square test. A logistic regression model was used to further assess the impact 
of NSAID use on persistence, controlling for baseline characteristics. Results: The 
study cohort included a total of 108 biologic naïve AS patients, 72 with use of NSAIDs 
in the pre-index period. The mean age of the AS cohort was 42 years, with 70% of 
patients being male. Adalimumab, etanercept, and golimumab were initiated by 
61%, 28%, and 11% of patients, respectively. Persistence for at least 12 months with 
the index subcutaneous biologic was observed in 46.3% of the overall cohort, with 
similar results among those with and without NSAID use (47% vs 44%, respectively). 
Multivariate analysis confirmed similar persistence between those with and without 
pre-index NSAID (OR: 0.97; 95% CI: 0.39-2.44). cOnclusiOns: Findings from this 
German study showed that less than half of AS patients are persistent with the 
index subcutaneous biologic over a 12 month period. Results were similar irrespec-
tive of prior use of NSAIDs.
